Buchumschlag

Determining value in health technology assessment: stay the course or tack away?

The economic evaluation of new health technologies to assess whether the value of the expected health benefits warrants the proposed additional costs has become an essential step in making novel interventions available to patients. This assessment of value is problematic because there exists no natu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Caro, J. Jaime (VerfasserIn) , Schlander, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2019
In: PharmacoEconomics
Year: 2018, Jahrgang: 37, Heft: 3, Pages: 293-299
ISSN:1179-2027
DOI:10.1007/s40273-018-0742-2
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s40273-018-0742-2
Verlag, Volltext: https://link.springer.com/article/10.1007%2Fs40273-018-0742-2
Volltext
Verfasserangaben:J. Jaime Caro, John E. Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord, Michael Schlander

MARC

LEADER 00000caa a2200000 c 4500
001 1676511679
003 DE-627
005 20220816223113.0
007 cr uuu---uuuuu
008 190911r20192018xx |||||o 00| ||eng c
024 7 |a 10.1007/s40273-018-0742-2  |2 doi 
035 |a (DE-627)1676511679 
035 |a (DE-599)KXP1676511679 
035 |a (OCoLC)1341242778 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Caro, J. Jaime  |e VerfasserIn  |0 (DE-588)1194573975  |0 (DE-627)1676782656  |4 aut 
245 1 0 |a Determining value in health technology assessment  |b stay the course or tack away?  |c J. Jaime Caro, John E. Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord, Michael Schlander 
264 1 |c 2019 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a First online: 09 November 2018 
500 |a Gesehen am 11.09.2019 
520 |a The economic evaluation of new health technologies to assess whether the value of the expected health benefits warrants the proposed additional costs has become an essential step in making novel interventions available to patients. This assessment of value is problematic because there exists no natural means to measure it. One approach is to assume that society wishes to maximize aggregate health, measured in terms of quality-adjusted life-years (QALYs). Commonly, a single ‘cost-effectiveness’ threshold is used to gauge whether the intervention is sufficiently efficient in doing so. This approach has come under fire for failing to account for societal values that favor treating more severe illness and ensuring equal access to resources, regardless of pre-existing conditions or capacity to benefit. Alternatives involving expansion of the measure of benefit or adjusting the threshold have been proposed and some have advocated tacking away from the cost per QALY entirely to implement therapeutic area-specific efficiency frontiers, multicriteria decision analysis or other approaches that keep the dimensions of benefit distinct and value them separately. In this paper, each of these alternative courses is considered, based on the experiences of the authors, with a view to clarifying their implications. 
534 |c 2018 
700 1 |a Schlander, Michael  |d 1959-  |e VerfasserIn  |0 (DE-588)1036904652  |0 (DE-627)751411957  |0 (DE-576)389587710  |4 aut 
773 0 8 |i Enthalten in  |t PharmacoEconomics  |d Berlin [u.a.] : Springer, 1992  |g 37(2019), 3, Seite 293-299  |h Online-Ressource  |w (DE-627)327645717  |w (DE-600)2043876-X  |w (DE-576)273880853  |x 1179-2027  |7 nnas  |a Determining value in health technology assessment stay the course or tack away? 
773 1 8 |g volume:37  |g year:2019  |g number:3  |g pages:293-299  |g extent:7  |a Determining value in health technology assessment stay the course or tack away? 
856 4 0 |u https://doi.org/10.1007/s40273-018-0742-2  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007%2Fs40273-018-0742-2  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190911 
993 |a Article 
994 |a 2019 
998 |g 1036904652  |a Schlander, Michael  |m 1036904652:Schlander, Michael  |d 50000  |e 50000PS1036904652  |k 0/50000/  |p 7  |y j 
999 |a KXP-PPN1676511679  |e 3514550573 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1676511679"],"doi":["10.1007/s40273-018-0742-2"]},"origin":[{"dateIssuedDisp":"2019","dateIssuedKey":"2019"}],"name":{"displayForm":["J. Jaime Caro, John E. Brazier, Jonathan Karnon, Peter Kolominsky-Rabas, Alistair J. McGuire, Erik Nord, Michael Schlander"]},"recId":"1676511679","person":[{"display":"Caro, J. Jaime","family":"Caro","role":"aut","given":"J. Jaime"},{"family":"Schlander","role":"aut","given":"Michael","display":"Schlander, Michael"}],"title":[{"title_sort":"Determining value in health technology assessment","subtitle":"stay the course or tack away?","title":"Determining value in health technology assessment"}],"physDesc":[{"extent":"7 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"recId":"327645717","disp":"Determining value in health technology assessment stay the course or tack away?PharmacoEconomics","id":{"eki":["327645717"],"issn":["1179-2027"],"zdb":["2043876-X"]},"origin":[{"publisherPlace":"Berlin [u.a.] ; Auckland","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisher":"Springer ; Adis Intern."}],"part":{"year":"2019","issue":"3","pages":"293-299","volume":"37","extent":"7","text":"37(2019), 3, Seite 293-299"},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 15.05.14"],"language":["eng"],"pubHistory":["1.1992 -"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"PharmacoEconomics","subtitle":"economic evaluations of drug therapy in disease management","title":"PharmacoEconomics"}]}],"note":["First online: 09 November 2018","Gesehen am 11.09.2019"]} 
SRT |a CAROJJAIMEDETERMININ2019 

Ähnliche Einträge